CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

References

• Bianchi C, Bianchi T. Global mesothelioma epidemic: Trend and features. Indian J Occup Environ Med. 2014;18:82-8. doi:10.4103/0019-5278.146897. PMID:25568603.
   PubMedGoogle Scholar
• Izzi V, Masuelli L, Tresoldi I, Foti C, Modesti A, Bei R. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett. 2012;322:18-34. doi:10.1016/j.canlet.2012.02.034. PMID:22394996.
   PubMed Web of Science ®Google Scholar
• Thapa B, Watkins DN, John T. Immunotherapy for malignant mesothelioma: reality check. Expert Rev Anticancer Ther. 2016;16:1167-1176. doi:10.1080/14737140.2016.1241149. PMID:27669108.
   PubMed Web of Science ®Google Scholar
• Lievense LA, Sterman DH, Cornelissen R, Aerts JG. Checkpoint Blockade in Lung Cancer and Mesothelioma. Am J Respir Crit Care Med. 2017;196:274-282. doi:10.1164/rccm.201608-1755CI. PMID:28252315.
   PubMed Web of Science ®Google Scholar
• Whilding LM, Maher J. CAR T-cell immunotherapy: The path from the by-road to the freeway? Mol Oncol. 2015;9:1994-2018. doi:10.1016/j.molonc.2015.10.012. PMID:26563646.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6:261ra151. doi:10.1126/scitranslmed.3010162. PMID:25378643.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130-44. doi:10.1172/JCI83092. PMID:27454297.
   PubMed Web of Science ®Google Scholar
• Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jungel A, Marroquin Belaunzaran O, Stahel R, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013;11:187. doi:10.1186/1479-5876-11-187. PMID:23937772.
   PubMed Web of Science ®Google Scholar
• Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Pure E, Milone MC, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res. 2014;20:4262-73. doi:10.1158/1078-0432.CCR-13-2627. PMID:24919573.
   PubMed Web of Science ®Google Scholar
• Mayor M, Zeltsman M, McGee E, Adusumilli PS. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial. Immunotherapy. 2016;8:491-4. doi:10.2217/imt-2016-0008. PMID:27140404.
   PubMed Web of Science ®Google Scholar
• O'Hara M, Stashwick C, Haas AR, Tanyi JL. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy. 2016;8:449-60. doi:10.2217/imt.16.4. PMID:26973126.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112-20. doi:10.1158/2326-6066.CIR-13-0170. PMID:24579088.
   PubMed Web of Science ®Google Scholar
• Jeannon JP, Ofu E, Balfour A, Bowman J, Simo R. The natural history of untreated squamous cell carcinoma of the head and neck: how we do it. Clin Otolaryngol. 2011;36:384-8. doi:10.1111/j.1749-4486.2011.02325.x. PMID:21848553.
   PubMed Web of Science ®Google Scholar
• Papa S, van Schalkwyk M, Maher J. Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors. Methods Mol Biol. 2015;1317:365-82. doi:10.1007/978-1-4939-2727-2_21. PMID:26072418.
   PubMedGoogle Scholar
• Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, et al. Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells. Cancer Lett. 2017;393:52-9. doi:10.1016/j.canlet.2017.02.015. PMID:28223167.
   PubMed Web of Science ®Google Scholar
• Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Muller KM. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. Journal of cancer research and clinical oncology 1998;124:291-6. doi:10.1007/s004320050171. PMID:9692834.
   PubMed Web of Science ®Google Scholar
• Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 2009;30:1097-105. doi:10.1093/carcin/bgp097. PMID:19380521.
   PubMed Web of Science ®Google Scholar
• Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006;66:352-61. doi:10.1158/0008-5472.CAN-04-4567. PMID:16397249.
   PubMed Web of Science ®Google Scholar
• Levallet G, Vaisse-Lesteven M, Le Stang N, Ilg AG, Brochard P, Astoul P, Pairon JC, Bergot E, Zalcman G, Galateau-Salle F. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2012;7:599-606. doi:10.1097/JTO.0b013e3182417da5. PMID:22246193.
   PubMed Web of Science ®Google Scholar
• Bronte G, Incorvaia L, Rizzo S, Passiglia F, Galvano A, Rizzo F, Rolfo C, Fanale D, Listi A, Natoli C, et al. The resistance related to targeted therapy in malignant pleural mesothelioma: why has not the target been hit yet? Critical Reviews in Oncology/ Hematology. 2016;107:20-32. doi:10.1016/j.critrevonc.2016.08.011. PMID:27823648.
   PubMed Web of Science ®Google Scholar
• Thayaparan T, Spicer JF, Maher J. The role of the HGF/Met axis in mesothelioma. Biochemical Society transactions. 2016;44:363-70. doi:10.1042/BST20150252. PMID:27068941.
   PubMed Web of Science ®Google Scholar
• Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, et al. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PloS one. 2014;9:e105919. doi:10.1371/journal.pone.0105919. PMID:25221930.
   PubMed Web of Science ®Google Scholar
• Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. Curr Drug Targets. 2014;15:1331-40. doi:10.2174/1389450116666141205160924. PMID:25483224.
   PubMed Web of Science ®Google Scholar
• Cioce V, Csaky KG, Chan AM, Bottaro DP, Taylor WG, Jensen R, Aaronson SA, Rubin JS. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. J Biol Chem 1996;271:13110-5. doi:10.1074/jbc.271.22.13110. PMID:8662798.
   PubMed Web of Science ®Google Scholar
• Lokker NA, Godowski PJ. Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1. J Biol Chem 1993;268:17145-50. PMID:8349603.
   PubMed Web of Science ®Google Scholar
• Jakubczak JL, LaRochelle WJ, Merlino G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Molecular and cellular biology 1998;18:1275-83. doi:10.1128/MCB.18.3.1275. PMID:9488442.
   PubMed Web of Science ®Google Scholar
• Simon Davis DA, Parish CR. Heparan sulfate: a ubiquitous glycosaminoglycan with multiple roles in immunity. Front Immunol. 2013;4:470. doi:10.3389/fimmu.2013.00470. PMID:24391644.
   PubMed Web of Science ®Google Scholar
• Lietha D, Chirgadze DY, Mulloy B, Blundell TL, Gherardi E. Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J. 2001;20:5543-55. doi:10.1093/emboj/20.20.5543. PMID:11597998.
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002;20:70-5. doi:10.1038/nbt0102-70. PMID:11753365.
   PubMed Web of Science ®Google Scholar
• Jones DS, 2nd, Tsai PC, Cochran JR. Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists. Proc Natl Acad Sci U S A. 2011;108:13035-40. doi:10.1073/pnas.1102561108. PMID:21788476.
   PubMed Web of Science ®Google Scholar
• Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RM, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, et al. Targeting of Aberrant alphavbeta6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. Mol Ther. 2017;25:259-73. doi:10.1016/j.ymthe.2016.10.012. PMID:28129120.
   PubMed Web of Science ®Google Scholar
• Davies DM, Foster J, Van Der Stegen SJ, Parente-Pereira AC, Chiapero-Stanke L, Delinassios GJ, Burbridge SE, Kao V, Liu Z, Bosshard-Carter L, et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med. 2012;18:565-76. doi:10.2119/molmed.2011.00493. PMID:22354215.
   PubMed Web of Science ®Google Scholar
• Wilkie S, Burbridge SE, Chiapero-Stanke L, Pereira AC, Cleary S, van der Stegen SJ, Spicer JF, Davies DM, Maher J. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem. 2010;285:25538-44. doi:10.1074/jbc.M110.127951. PMID:20562098.
   PubMed Web of Science ®Google Scholar
• Volz Y, Koschut D, Matzke-Ogi A, Dietz MS, Karathanasis C, Richert L, Wagner MG, Mely Y, Heilemann M, Niemann HH, et al. Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Biosci Rep. 2015;35. doi:10.1042/BSR20150093. PMID:26181364.
   PubMed Web of Science ®Google Scholar
• Hartmann G, Prospero T, Brinkmann V, Ozcelik C, Winter G, Hepple J, Batley S, Bladt F, Sachs M, Birchmeier C, et al. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Current biology: CB 1998;8:125-34. doi:10.1016/S0960-9822(98)70059-4. PMID:9443912.
   PubMed Web of Science ®Google Scholar
• Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002;99:1405-10. doi:10.1182/blood.V99.4.1405. PMID:11830493.
   PubMed Web of Science ®Google Scholar
• Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol. 2000;18:405-9. doi:10.1038/74455. PMID:10748520.
   PubMed Web of Science ®Google Scholar
• Bellosta P, Iwahori A, Plotnikov AN, Eliseenkova AV, Basilico C, Mohammadi M. Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis. Molecular and cellular biology. 2001;21:5946-57. doi:10.1128/MCB.21.17.5946-5957.2001. PMID:11486033.
   PubMed Web of Science ®Google Scholar
• Nasimuzzaman M, Persons DA. Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells. Mol Ther. 2012;20:1158-66. doi:10.1038/mt.2012.41. PMID:22434139.
   PubMed Web of Science ®Google Scholar
• Heidari-Hamedani G, Vives RR, Seffouh A, Afratis NA, Oosterhof A, van Kuppevelt TH, Karamanos NK, Metintas M, Hjerpe A, Dobra K, et al. Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma. Cell Signal. 2015;27:2054-67. doi:10.1016/j.cellsig.2015.07.017. PMID:26210886.
   PubMed Web of Science ®Google Scholar
• Komarowska I, Coe D, Wang G, Haas R, Mauro C, Kishore M, Cooper D, Nadkarni S, Fu H, Steinbruchel DA, et al. Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release. Immunity. 2015;42:1087-99. doi:10.1016/j.immuni.2015.05.014. PMID:26070483.
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD, Jr., et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res. 2015;3:356-67. doi:10.1158/2326-6066.CIR-14-0186. PMID:25600436.
   PubMed Web of Science ®Google Scholar
• Catlow KR, Deakin JA, Wei Z, Delehedde M, Fernig DG, Gherardi E, Gallagher JT, Pavao MS, Lyon M. Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density. J Biol Chem. 2008;283:5235-48. doi:10.1074/jbc.M706589200. PMID:18156180.
   PubMed Web of Science ®Google Scholar
• Johansson CM. Biophysical characterisation of the hepatocyte growth factor – glycosaminglycan interaction. PhD Thesis submission to the University of Edinburgh. 2011. https://www.era.lib.ed.ac.uk/handle/1842/9904.
   Google Scholar
• Zhou H, Casas-Finet JR, Heath Coats R, Kaufman JD, Stahl SJ, Wingfield PT, Rubin JS, Bottaro DP, Byrd RA. Identification and dynamics of a heparin-binding site in hepatocyte growth factor. Biochemistry 1999;38:14793-802. doi:10.1021/bi9908641. PMID:10555961.
   PubMed Web of Science ®Google Scholar
• Merkulova-Rainon T, England P, Ding S, Demerens C, Tobelem G. The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor. J Biol Chem. 2003;278:37400-8. doi:10.1074/jbc.M212768200. PMID:12847110.
   PubMed Web of Science ®Google Scholar
• Kaur S, Kuznetsova SA, Pendrak ML, Sipes JM, Romeo MJ, Li Z, Zhang L, Roberts DD. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Bio Chem. 2011;286:14991-5002. doi:10.1074/jbc.M110.179663. PMID:21343308.
   PubMed Web of Science ®Google Scholar
• Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J Virol. 2005;79:12692-702. doi:10.1128/JVI.79.20.12692-12702.2005. PMID:16188972.
   PubMed Web of Science ®Google Scholar
• Fadnes B, Husebekk A, Svineng G, Rekdal O, Yanagishita M, Kolset SO, Uhlin-Hansen L. The proteoglycan repertoire of lymphoid cells. Glycoconj J. 2012;29:513-23. doi:10.1007/s10719-012-9427-9. PMID:22777011.
   PubMed Web of Science ®Google Scholar
• Ross J, Gherardi E, Mallorqui-Fernandez N, Bocci M, Sobkowicz A, Rees M, Rowe A, Ellmerich S, Massie I, Soeda J, et al. Protein engineered variants of hepatocyte growth factor/scatter factor promote proliferation of primary human hepatocytes and in rodent liver. Gastroenterology. 2012;142:897-906. doi:10.1053/j.gastro.2011.12.006. PMID:22178588.
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581-90.doi:10.1038/nm.3838. PMID:25939063.
   PubMed Web of Science ®Google Scholar
• van der Stegen SJ, Davies DM, Wilkie S, Foster J, Sosabowski JK, Burnet J, Whilding LM, Petrovic RM, Ghaem-Maghami S, Mather S, et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? J Immunol. 2013;191:4589-98. doi:10.4049/jimmunol.1301523. PMID:24062490.
   PubMed Web of Science ®Google Scholar
• Papa S, Adami AA, Metoudi M, Achkova DY, van Schalkwyk M, Parente-Pereira AC, Bosshard-Carter L, Whilding LM, van der Stegen S, Davies D.M., et al. Online Proceedings of the Annual Meeting of the American Association for Cancer Research. http://wwwabstractsonlinecom/pp8/ – !/4292/presentation/12333. 2017.
   Google Scholar
• Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, et al. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. Cancer Res. 2015;75:3373-83. doi:10.1158/0008-5472.CAN-15-0356. PMID:26141862.
   PubMed Web of Science ®Google Scholar
• Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, Burbridge SE, Box C, Eccles SA, Maher J. Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling. J Clin Immunol. 2012;32:1059-70. doi:10.1007/s10875-012-9689-9. PMID:22526592.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31:71-5. doi:10.1038/nbt.2459. PMID:23242161.
   PubMed Web of Science ®Google Scholar
• Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105:4247-54. doi:10.1182/blood-2004-11-4564. PMID:15728125.
   PubMed Web of Science ®Google Scholar
• Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180:4901-9. doi:10.4049/jimmunol.180.7.4901. PMID:18354214.
   PubMed Web of Science ®Google Scholar